Core Insights - Warren Buffett is no longer the CEO of Berkshire Hathaway but remains chairman and involved in major decisions [1] - Buffett's investing wisdom continues to be relevant, particularly his two-step test for stock evaluation [2][4] Investment Strategy - The first step in Buffett's test is to determine if earnings can be estimated for at least five years [5] - The second step involves checking if the stock's valuation is reasonable relative to the lower end of the projected earnings range [6] - Buffett emphasizes focusing on stocks within one's "circle of competence" to improve the accuracy of earnings projections [8] Market Analysis - As of early 2026, there are limited stocks that pass Buffett's test, with Berkshire holding a record-high cash stockpile [10] - AbbVie is highlighted as a strong candidate, having navigated its Humira patent cliff and expected to deliver robust earnings growth, with a current market cap of $405 billion and a dividend yield of 2.86% [11][12] - Nucor is another potential stock, benefiting from data center construction and infrastructure investments, with a low forward price-to-earnings ratio of 14.5 [11][12]

Market Predictions for 2026 - The S&P 500 is expected to deliver single-digit gains in 2026, ending a streak of double-digit gains over the past three years, but no major market sell-off is anticipated due to strong economic and corporate earnings [4][5] - Small- and mid-cap stocks are predicted to outperform larger stocks, with Mirum Pharmaceuticals highlighted as a potential winner after its share price nearly doubled in 2025, and expected positive results from clinical studies in 2026 [6][7][8] - The AI sector is expected to shift from hype to tangible returns, with Alphabet predicted to continue benefiting from its Google Cloud unit and agentic AI technology, which is anticipated to drive growth [9][10][12] - The renewable energy sector is expected to continue its rebound, driven by strong AI growth and increased demand for energy to power data centers, with Brookfield Renewable and Clearway Energy expected to perform well [13][15] - Political dynamics in the mid-term election year are expected to create volatility in the stock market, but once the uncertainty fades, stocks are predicted to move higher, with potential winners in the cannabis industry if Democrats gain control [16][18]

南财智讯1月4日电，北大医药公告，公司拟以不超过2266.88万元收购大新药业9.75%股权。交易完成 后，公司将持有大新药业9.75%股权。该事项构成关联交易，但不构成重大资产重组。大新药业是国家 火炬计划重点高新技术企业，主要从事原料药与医药中间体的研发生产，涵盖营养药物、血脂调节、抗 生素等多个系列，并开展CDMO合作业务。 ...

四川正加速推进集采药品下沉基层，不久的将来老百姓就不用为买集采药品专门去大医院，在家门口的 药店、民营医院或村卫生室就能买到。2025年12月30日，四川省医保局发出相关通知，将采取措施进一 步促进集采药品进基层医疗机构、进民营医疗机构、进零售药店（以下简称"三进"）。 "集采药品'三 进'，旨在进一步扩大集采政策覆盖面，让人民群众能在更多渠道、就近就便享受到集采改革成果。"省 医保局相关负责人表示，四川将进一步扩大集采覆盖范围，公立基层医疗机构，包括乡镇卫生院、社区 卫生服务中心/站、村卫生室等，按政策规定参加集采。鼓励并引导定点民营医疗机构、定点零售药店 参加集采，并配备一定数量集采药品。（四川日报） ...

Core Viewpoint - Novo Nordisk is expected to recover from a challenging 2025, with potential growth in 2026 driven by new product approvals and pipeline advancements [1][2]. Group 1: New Approvals - Novo Nordisk secured significant label expansions for its weight management drug Wegovy, now approved for metabolic dysfunction-associated steatohepatitis (MASH) and has an oral version approved for weight loss [3][5]. - Wegovy's MASH indication has the potential to generate over $1 billion in sales, benefiting from Novo Nordisk's larger resources compared to competitors like Madrigal Pharmaceuticals [6]. - The oral formulation of Wegovy is expected to attract patients preferring daily pills over weekly injections, contributing to improved top-line growth [7]. Group 2: Pipeline Progress - Novo Nordisk aims to regain market share in the GLP-1 market, with ongoing pipeline candidates expected to contribute positively [8]. - A promising candidate, amycretin, is in phase 3 studies and mimics the actions of GLP-1 and amylin, with interim data anticipated next year [9]. - Other investigational products, such as UBT251, could also enhance Novo Nordisk's market position if they show strong progress [10]. Group 3: Financial Outlook - The company is expected to see strong sales from Wegovy and Ozempic in the coming years, alongside new launches like CagriSema [11]. - Novo Nordisk's shares are currently valued at around 14 times forward earnings, which is lower than the healthcare sector average of 18.4, indicating a potential buying opportunity [12].

Core Insights - The obesity drugs market is experiencing a revival after a period of consolidation that began in early 2024, attracting healthcare investors since the "great market rotation" themes of Q4 2025 [1] Group 1: Market Trends - The healthcare sector is seeing renewed interest from investors, particularly in obesity drugs, following a consolidation phase [1] - The "great market rotation" in Q4 2025 has contributed to this renewed investor enthusiasm [1] Group 2: Investment Strategy - The company focuses on identifying attractive risk/reward opportunities that are supported by strong price action, aiming to generate alpha above the S&P 500 [1] - The investment approach combines price action analysis with fundamental analysis, avoiding overhyped stocks while targeting undervalued stocks with recovery potential [1] - The investment group specializes in high-potential opportunities across various sectors, emphasizing stocks with strong growth potential and appealing turnaround plays [1]

Core Insights - The obesity drugs market is experiencing a revival after a period of consolidation that began in early 2024, attracting healthcare investors since the "great market rotation" themes of Q4 2025 [1] Group 1: Market Trends - The healthcare sector is seeing renewed interest from investors, particularly in obesity drugs, following a consolidation phase [1] - The "great market rotation" in Q4 2025 has contributed to this renewed investor enthusiasm [1] Group 2: Investment Strategy - The company focuses on identifying attractive risk/reward opportunities that are supported by strong price action, aiming to generate alpha above the S&P 500 [1] - The investment approach combines price action analysis with fundamental analysis, avoiding overhyped stocks while targeting undervalued stocks with recovery potential [1] - The investment group specializes in high-potential opportunities across various sectors, emphasizing stocks with strong growth potential and appealing turnaround plays [1]

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to alleged misstatements regarding the progress of its prostate cancer drug TLX591 and deficiencies in its third-party manufacturing processes, leading to significant investor losses [2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in stock value [2][7]. - The SEC is investigating the company's disclosures related to the development of its therapeutic candidates, suggesting misleading statements about their advancement [7]. - The FDA rejected the Zircaix application, citing severe deficiencies in Chemistry, Manufacturing, and Controls (CMC), and issued Form 483 notices to two third-party supply chain partners, revealing foundational weaknesses that were allegedly concealed [7]. Allegations of Misstatements - The complaint alleges that Telix and its executives materially overstated the developmental progress of its therapeutic candidates and misrepresented the reliability and regulatory compliance of its third-party supply chain and manufacturing partners [2][3]. - Documented failures in regulatory compliance were allegedly concealed, making the company's claims of "great progress" and "truly global manufacturing capability" materially false [3]. Investor Impact - The cumulative effect of the regulatory disclosures led to a sharp decline in Telix ADSs, with a notable 21% drop following the final regulatory news, resulting in significant damages for investors who purchased TLX ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 03, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a l ...

Company Overview - AbbVie is a pharmaceutical leader with a strong business model that generates consistent revenue and earnings through economic cycles, making it resilient even during recessions [4] - The company has a diversified portfolio across multiple therapeutic areas, including immunology, neuroscience, and oncology, with top-selling products like Skyrizi and Rinvoq [5] Financial Performance - AbbVie has a current market capitalization of $405 billion and a gross margin of 69.68% [10][7] - The company has a dividend yield of 2.86% and is recognized as a Dividend King, having increased its payouts for 54 consecutive years [8] Growth Potential - AbbVie has a robust pipeline and the capability to acquire smaller drugmakers or enter licensing agreements to enhance its product offerings [7] - The company is projected to deliver solid long-term returns, with an investment of $50,000 potentially growing to approximately $1,000,000 over 30 years at a compound annual growth rate (CAGR) of 10.5% [11] Market Position - AbbVie has successfully navigated the loss of patent exclusivity for its key product Humira in 2023, indicating strong underlying business fundamentals [5][7] - The company’s ability to maintain consistent performance through good and bad times positions it well for long-term success [7]